NCT05544032|Unknown
Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)
1 other identifier
I-34176-25-07
Study Type
expanded_access
Target
N/A
Locations
0 countries
Sites
N/A
Timeline
RegisteredSep 2022
Brief Summary
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 14, 2022
Completed2 days until next milestone
First Posted
Study publicly available on registry
September 16, 2022
CompletedLast Updated
October 8, 2025
Status Verified
October 1, 2025
First QC Date
September 14, 2022
Last Update Submit
October 3, 2025
Conditions
Keywords
Chronic Graft Vs. Host DiseasecGVHD
Interventions
axatilimabDRUG
Treatment with axatilimab includes receiving intravenous (IV) doses of axatilimab every 2 weeks
Also known as: INCA34176
Eligibility Criteria
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Interventions
axatilimab
Central Study Contacts
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 14, 2022
First Posted
September 16, 2022
Last Updated
October 8, 2025
Record last verified: 2025-10